ALTEOGEN Inc. (KOSDAQ:196170)

Market Cap	19.85T
Revenue (ttm)	102.85B
Net Income (ttm)	60.69B
Shares Out	53.30M
EPS (ttm)	1,142.41
PE Ratio	327.11
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	360,992
Average Volume	886,026
Open	375,500
Previous Close	372,500
Day's Range	360,500 - 377,500
52-Week Range	156,200 - 459,500
Beta	1.25
RSI	44.11
Earnings Date	Mar 10, 2025

About ALTEOGEN

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 145
• Stock Exchange: KOSDAQ
• Ticker Symbol: 196170